EN | RU
EN | RU

Help Support

Back

Use of galcanezumab in real life for high frequency episodic and chronic migraine prophylaxis

Use of galcanezumab in real life for high frequency episodic and chronic migraine prophylaxis Use of galcanezumab in real life for high frequency episodic and chronic migraine prophylaxis
Use of galcanezumab in real life for high frequency episodic and chronic migraine prophylaxis Use of galcanezumab in real life for high frequency episodic and chronic migraine prophylaxis

This real-life multicenter prospective cohort study [GARLIT] was performed to examine the overall efficacy of galcanezumab (humanized monoclonal antibody) in high-frequency episodic migraine (HFEM) and chronic migraine (CM) prophylaxis for 6 months.

See All

Key take away

As compared to the randomized controlled trials, the use of galcanezumab was well-tolerated, safe, and appeared more effective in real life.

Background

This real-life multicenter prospective cohort study [GARLIT] was performed to examine the overall efficacy of galcanezumab (humanized monoclonal antibody) in high-frequency episodic migraine (HFEM) and chronic migraine (CM) prophylaxis for 6 months.

Method

Executed between November 2019 to January 2021, a total of 163 clinically eligible adult patients with HFEM and CM patients were enrolled. The initial loading dose of galcanezumab was 240 mg which was later set to 120 mg subcutaneous injection once-a-month. The variation in monthly migraine days (MMDs) and headache days (MHDs) in HFEM and CM patients after a period of 6 months was the primary endpoint. 

Result

Out of 163 patients (mean age of 47.1 ± 11.7 years), 80.5% were women and 79.8% had CM. After 6 months, MMDs and MHDs decreased by 8 and 13 days in HFEM and CM patients. A considerable reduction in painkiller intake per month, numerical rating scale (NRS), Headache Impact Test-6 (HIT-6), and Migraine Disability Assessment (MIDAS) score was observed.

Ten patients (6.1%) discontinued due to inefficacy and were regarded as non-responders.  After 6 months, 76.5% and 63.5% responders (≥50% responder rates) were observed in the HFEM and CM group, respectively.

Among CM patients, these responders exhibited a lower body mass index and had failed a lesser number of preventive therapies compared to non-responders. About 77.2% of CM patients transformed to EM, and 82.0% stopped medication overuse (MO) after 6 months. Non-serious adverse events were reported in 10.3% of patients.

Conclusion

Substantial benefits of galcanezumab were noted in lessening the migraine attacks in real-life but not randomized controlled trials. This can be due to normal body weight and lesser unsuccessful preventive treatments being positively linked with its effectiveness in patients with chronic migraine.

Source:

The Journal of Headache and Pain

Article:

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Authors:

Fabrizio Vernieri et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: